Press Releases
Date Title and Summary View
Oct 8, 2014 - Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV - - Three preclinical posters on ACH-3422, uridine-analog nucleotide prodrug, to be presented - NEW HAVEN, Conn., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Achillion Ph...
Aug 19, 2014 NEW HAVEN, Conn., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's sec...
Aug 15, 2014 NEW HAVEN, Conn., Aug. 15, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve...
Aug 7, 2014 NEW HAVEN, Conn., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2014 and provided an update on the Company's portfolio of clinical stage compounds being developed for the treatment of the hepatitis C virus (HCV). For the second quarter ...
Jul 1, 2014 NEW HAVEN, Conn., July 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that it has been added to the Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market changes in the past year. Annual reconstitution of Russell's U.S. indexes captures t...
Jun 11, 2014 NEW HAVEN, Conn., June 11, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences: 2014 Wells Fargo Healthcare Conference on Wednesday, June 18, 2014 at 1:15 p.m. ET at the InterContinental Hotel in ...
Jun 10, 2014 Initial cohort of HCV-infected patients begin dosing with ACH-3422 for seven daysClinical trials may continue evaluating 200 mg of sovaprevir for HCV-infected patientsTimelines for reporting proof-of-concept results with ACH-3422, a proprietary uridine-analog nucleotide polymerase inhibitor, during the fall of 2014 and initiating all-oral combinati...
May 7, 2014 NEW HAVEN, Conn., May 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2014. For the first quarter of 2014, the Company reported a net loss of $16.1 million or $0.17 per share, compared with a net loss of $11.7 million or $0.14 per share for the first qua...
May 1, 2014 NEW HAVEN, Conn., May 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at three upcoming investor conferences: Deutsche Bank Securities 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:10 p.m. ET at the InterCo...
Apr 30, 2014 - Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug -- Initiated Phase 2 Study Evaluating ACH-3102, Second-Generation NS5A Inhibitor, With Sofosbuvir for 8 Weeks of Treatment or Less in Genotype 1 HCV Treatment-Naïve Patients - NEW HAVEN, Conn.,...
1
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue